CD8A and neoplasm: Immune checkpoint inhibitors (ICIs) are often monoclonal antibodies that destroy malignant tumor cells by inhibiting co-suppressive signaling pathways to reactivate the immune response and increase cytotoxic CD8+T lymphocytes [1].